HK1170224A1 - 有效作為黃嘌呤氧化酶抑制劑的新化合物、該化合物的製備方法和含有該化合物的藥物組合物 - Google Patents

有效作為黃嘌呤氧化酶抑制劑的新化合物、該化合物的製備方法和含有該化合物的藥物組合物

Info

Publication number
HK1170224A1
HK1170224A1 HK12110873.7A HK12110873A HK1170224A1 HK 1170224 A1 HK1170224 A1 HK 1170224A1 HK 12110873 A HK12110873 A HK 12110873A HK 1170224 A1 HK1170224 A1 HK 1170224A1
Authority
HK
Hong Kong
Prior art keywords
same
preparing
pharmaceutical composition
composition containing
novel compounds
Prior art date
Application number
HK12110873.7A
Other languages
English (en)
Inventor
宋正旭
金根泰
崔盛弼
鄭哲圭
朴德星
崔恩寶
金泰勳
朴賢靜
朴完洙
朴喜戌
丘冀哲
．阿特莫弗
Original Assignee
株式會社 生命科學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1170224(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 株式會社 生命科學 filed Critical 株式會社 生命科學
Publication of HK1170224A1 publication Critical patent/HK1170224A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12110873.7A 2009-10-07 2012-10-30 有效作為黃嘌呤氧化酶抑制劑的新化合物、該化合物的製備方法和含有該化合物的藥物組合物 HK1170224A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07
PCT/KR2010/006760 WO2011043568A2 (en) 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Publications (1)

Publication Number Publication Date
HK1170224A1 true HK1170224A1 (zh) 2013-02-22

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110873.7A HK1170224A1 (zh) 2009-10-07 2012-10-30 有效作為黃嘌呤氧化酶抑制劑的新化合物、該化合物的製備方法和含有該化合物的藥物組合物

Country Status (27)

Country Link
US (1) US8729273B2 (zh)
EP (1) EP2467378B1 (zh)
JP (1) JP5702392B2 (zh)
KR (1) KR101751325B1 (zh)
CN (1) CN102574839B (zh)
AP (1) AP3346A (zh)
AR (1) AR078504A1 (zh)
AU (1) AU2010304091B2 (zh)
BR (1) BR112012007828B8 (zh)
CA (1) CA2774133C (zh)
CL (1) CL2012000738A1 (zh)
CO (1) CO6430501A2 (zh)
EA (1) EA021025B1 (zh)
EC (1) ECSP12011793A (zh)
ES (1) ES2599829T3 (zh)
HK (1) HK1170224A1 (zh)
IL (1) IL218669A (zh)
MA (1) MA33880B1 (zh)
MX (1) MX2012003782A (zh)
MY (1) MY162813A (zh)
PE (1) PE20121088A1 (zh)
SG (1) SG179186A1 (zh)
TR (1) TR201203989T1 (zh)
TW (1) TWI423962B (zh)
UA (1) UA110197C2 (zh)
WO (1) WO2011043568A2 (zh)
ZA (1) ZA201202544B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
ES2765805T3 (es) * 2011-08-30 2020-06-11 Chdi Foundation Inc Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
ES2666918T3 (es) 2013-03-29 2018-05-08 Teijin Pharma Limited Derivado de pirazol
UA120856C2 (uk) 2014-07-17 2020-02-25 Кхді Фаундейшн, Інк. Способи та композиції для лікування розладів, пов'язаних з віл
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
KR102635986B1 (ko) * 2015-09-02 2024-02-08 선샤인 레이크 파르마 컴퍼니 리미티드 카르복시 치환된 (헤테로) 방향족 고리 유도체 및 이의 제조 방법과 용도
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
CN110612286A (zh) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
MX2020009287A (es) * 2018-06-01 2020-09-28 Autophagysciences Inc Nuevo compuesto y composicion farmaceutica que lo comprende.
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
US20240000750A1 (en) * 2020-11-04 2024-01-04 Lg Chem, Ltd. Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
AR124178A1 (es) * 2020-12-01 2023-02-22 Lg Chemical Ltd Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
EP4257124A4 (en) * 2020-12-01 2024-05-29 Lg Chem, Ltd. ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID AND METHOD FOR THE PREPARATION THEREOF
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
PE20240764A1 (es) 2021-04-16 2024-04-17 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
WO2022231261A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
CN117255785A (zh) * 2021-04-27 2023-12-19 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
US20240239768A1 (en) * 2021-04-27 2024-07-18 Lg Chem, Ltd. Method for preparing xanthine oxidase inhibitor
JP2024516040A (ja) 2021-04-29 2024-04-11 江▲蘇▼新元素医▲薬▼科技有限公司 キサンチンオキシダーゼ抑制剤
KR20220168172A (ko) * 2021-06-15 2022-12-22 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물
AR126164A1 (es) 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
US20240317685A1 (en) 2021-07-02 2024-09-26 Lg Chem, Ltd. Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
WO2023208103A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于痛风的化合物
WO2023208108A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
EP1296975A1 (en) * 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU6872701A (en) * 2000-07-10 2002-01-21 Bristol Myers Squibb Co Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
US20090286791A1 (en) * 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
CN101248074A (zh) 2005-07-01 2008-08-20 日本化学医药株式会社 黄嘌呤氧化酶抑制剂
AU2006300422A1 (en) * 2005-10-07 2007-04-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
WO2008126899A1 (ja) 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. ５員環へテロ環誘導体及びその医薬用途
AU2008239017B2 (en) 2007-04-11 2012-09-27 Kissei Pharmaceutical Co., Ltd. (Aza)indole derivative and use thereof for medical purposes
WO2010044404A1 (ja) 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 縮合複素環誘導体及びその医薬用途
AU2009303519B2 (en) 2008-10-16 2014-09-25 Automatic Bar Controls, Inc. Apparatus and method and turntable for on-demand distributing of a food product
US8785489B2 (en) * 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
WO2011036130A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators

Also Published As

Publication number Publication date
WO2011043568A2 (en) 2011-04-14
KR101751325B1 (ko) 2017-06-27
BR112012007828B1 (pt) 2021-01-12
CA2774133C (en) 2019-06-25
BR112012007828B8 (pt) 2021-05-25
EA201270520A1 (ru) 2012-10-30
TR201203989T1 (tr) 2012-09-21
SG179186A1 (en) 2012-05-30
TWI423962B (zh) 2014-01-21
CO6430501A2 (es) 2012-04-30
ECSP12011793A (es) 2012-05-30
ZA201202544B (en) 2012-12-29
MA33880B1 (fr) 2013-01-02
IL218669A (en) 2016-08-31
MY162813A (en) 2017-07-31
JP5702392B2 (ja) 2015-04-15
TW201118077A (en) 2011-06-01
KR20110037883A (ko) 2011-04-13
CA2774133A1 (en) 2011-04-14
AP3346A (en) 2015-07-31
US8729273B2 (en) 2014-05-20
AU2010304091A1 (en) 2012-04-19
CN102574839B (zh) 2015-11-25
MX2012003782A (es) 2012-08-31
UA110197C2 (ru) 2015-12-10
CN102574839A (zh) 2012-07-11
ES2599829T3 (es) 2017-02-03
AR078504A1 (es) 2011-11-09
US20120184582A1 (en) 2012-07-19
WO2011043568A3 (en) 2011-09-29
EP2467378A4 (en) 2013-04-24
CL2012000738A1 (es) 2012-09-14
JP2013507355A (ja) 2013-03-04
EP2467378A2 (en) 2012-06-27
EP2467378B1 (en) 2016-07-27
AU2010304091B2 (en) 2016-06-09
BR112012007828A2 (pt) 2016-03-08
EA021025B1 (ru) 2015-03-31
PE20121088A1 (es) 2012-08-17
AP2012006191A0 (en) 2012-04-30
IL218669A0 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
HUS1700051I1 (hu) Pirrolopiridin vegyületek, mint CDK inhibitorok
ZA201608799B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2464626A4 (en) PROCESSES, COMPOUNDS AND COMPOSITIONS FOR THE EXPORTS OF 1,3-PROPANE-SULFONIC ACID
HK1182098A1 (zh) 用作β-分泌酶 抑制劑的 -二氫- 噁嗪- -基-胺衍生物
ZA201208198B (en) Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same
WO2010093191A3 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
MY144726A (en) Diosmetin compounds, process for their preparation and pharmaceutical compositions containing them
HK1165798A1 (zh) 取代的吡咯衍生物、含這些衍生物的藥用組合物以及用其治療帕金森氏病的方法
EP2439198A4 (en) NOVEL PROCESS FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING ROSUVASTATIN, AND CORRESPONDING PREPARATION METHOD
ZA201103444B (en) Heteroaromatic compounds for use as hif inhibitors
EP2394993A4 (en) A NEW 2,6-SUBSTITUTED 3-NITROPYRIDINE DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
IL207183A (en) Dihydroindolone compounds, a process for their preparation and their pharmaceutical compositions
EP2285215A4 (en) NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
GB0800570D0 (en) Composition, process for preparation and method of use
IL203064B (en) A pharmaceutical preparation containing compound 11 - deoxy - prostaglandin and a method for stabilizing the compound
IL212850A0 (en) Novel method for the preparation of granulates of active constituents, and granulates as obtained
IL220621A (en) History of Naphthalene-1, 4-Diane, Pharmaceutical Preparations and Kit Containing Them for Use as Anticoagulants
AP2012006352A0 (en) AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same.
EP2366684A4 (en) NOVEL COMPOUND OF THE PTÉROCARPAQUINONES FAMILY, PROCESS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THESE NOVEL COMPOUNDS OF THE PTÉROCARPAQUINONES FAMILY, USES AND THERAPEUTIC METHOD
HK1153195A1 (en) Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
SI2332910T1 (sl) Novi derivati azabiciklo(3.2.0)hept-3-ila, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo